Benin Management CORP Continues to Hold Position in Edwards Lifesciences Corporation (EW)

Benin Management CORP maintained its stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,300 shares of the medical research company’s stock at the end of the second quarter. Benin Management CORP’s holdings in Edwards Lifesciences Corporation were worth $627,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in Edwards Lifesciences Corporation by 43.5% in the fourth quarter. GSA Capital Partners LLP now owns 3,354 shares of the medical research company’s stock valued at $314,000 after buying an additional 1,016 shares in the last quarter. South Texas Money Management Ltd. raised its stake in Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after buying an additional 211,119 shares in the last quarter. Financial Counselors Inc. raised its stake in Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after buying an additional 282 shares in the last quarter. American Century Companies Inc. raised its stake in Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock valued at $192,550,000 after buying an additional 137,934 shares in the last quarter. Finally, Advisor Partners LLC raised its stake in Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock valued at $460,000 after buying an additional 341 shares in the last quarter. Institutional investors and hedge funds own 83.96% of the company’s stock.

Edwards Lifesciences Corporation (NYSE EW) traded down 0.280% during midday trading on Wednesday, hitting $115.545. 689,013 shares of the stock traded hands. The firm has a market cap of $24.24 billion, a P/E ratio of 38.413 and a beta of 0.64. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company has a 50-day moving average price of $117.42 and a 200-day moving average price of $103.64.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Tuesday, April 25th. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.12. The firm had revenue of $883.50 million during the quarter, compared to analysts’ expectations of $776.51 million. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The company’s revenue was up 26.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.71 earnings per share. Analysts predict that Edwards Lifesciences Corporation will post $3.53 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by [[site]] and is the property of of [[site]]. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at [[permalink]].

EW has been the topic of several research reports. Vetr upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $116.04 price target on the stock in a research report on Thursday, May 4th. BidaskClub upgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Wednesday, April 26th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research report on Tuesday, July 18th. Finally, Stifel Nicolaus increased their price target on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the company a “buy” rating in a research report on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation has an average rating of “Buy” and a consensus price target of $116.99.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total value of $656,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. Insiders sold 252,101 shares of company stock valued at $28,141,680 over the last quarter. Corporate insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.